Current concepts in the pharmacotherapy of pseudobulbar affect

Drugs

Volumn 71, Issue 9, 2011, Pages 1193-1207

  Pioro, Erik P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Citalopram; Dextromethorphanquinidine; Emotional lability; Fluoxetine; Sertraline; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DEXTROMETHORPHAN; FLUOXETINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; QUINIDINE; SERTRALINE;

CARDIOTOXICITY; CONFUSION; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; EMOTIONAL INCONTINENCE; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HUMAN; LOW DRUG DOSE; NAUSEA; OFF LABEL DRUG USE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATHOLOGICAL CRYING; PATHOLOGICAL LAUGHTER; PLACEBO EFFECT; PSEUDOBULBAR AFFECT; PSYCHOLOGICAL RATING SCALE; REVIEW; RHINOPHARYNGITIS; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CRYING; DEXTROMETHORPHAN; DRUG COMBINATIONS; HUMANS; LAUGHTER; MOOD DISORDERS; OFF-LABEL USE; QUINIDINE;

EID: 79959728259     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11591450-000000000-00000     Document Type: Review

References (81)

1. Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci 2005 Fall; 17 (4): 447-54. (Pubitemid 41794037)
2. Parvizi J, Arciniegas DB, Bernardini GL, et al. Diagnosis and management of pathological laughter and crying. Mayo Clin Proc 2006 Nov; 81 (11): 1482-6. (Pubitemid 44685013)
3. House A, Dennis M, Molyneux A, et al. Emotionalism after stroke. BMJ 1989 Apr 15; 298 (6679): 991-4. (Pubitemid 19102775)
4. Brooks N. Personality change after severe head injury. Acta Neurochir Suppl (Wien) 1988; 44: 59-64.
5. Starkstein SE, Migliorelli R, Teson A, et al. Prevalence and clinical correlates of pathological affective display in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1995 Jul; 59 (1): 55-60.
6. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptommanagement, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009 Oct 13; 73 (15): 1227-33.
7. Feinstein A, Feinstein K, Gray T, et al. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 1997 Sep; 54 (9): 1116-21. (Pubitemid 27396479)
8. Gallagher JP. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989 Aug; 80 (2): 114-7. (Pubitemid 19214652)
9. Wilson SAK. Some problems in neurology, II: pathological laughing and crying. J Neurol Psychopathol 1924; IV: 299-333.
10. Darwin C. The expression of the emotions in man and animals. New York: D Appelton and Company, 1872.
11. Lawson IR, MacLeod RD. The use of imipramine ('Tofranil') and other psychotropic drugs in organic emotionalism. Br J Psychiatry 1969 Mar; 115 (520): 281-5.
12. Wolf JK, Santana HB, Thorpy M. Treatment of 'emotional incontinence' with levodopa. Neurology 1979 Oct; 29 (10): 1435-6.
13. Udaka F, Yamao S, Nagata H, et al. Pathologic laughing and crying treated with levodopa. Arch Neurol 1984 Oct; 41 (10): 1095-6. (Pubitemid 14041755)
14. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004 Oct 26; 63 (8): 1364-70. (Pubitemid 39426266)
15. Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010 Nov; 68 (5): 693-702.
16. Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006 May; 59 (5): 780-7. (Pubitemid 43673155)
17. Cummings JL, Arciniegas DB, Brooks BR, et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr 2006 Jun; 11 (6): 1-7.
18. Komurasaki Y, Yokoyama T, Ogura J, et al. Treatment of pathologic emotionality with thyrotropin-releasing hormone. Jpn J Psychiatry Neurol 1989 Dec; 43 (4): 665-8. (Pubitemid 20228958)
19. Pringle CE, Hudson AJ, Munoz DG, et al. Primary lateral sclerosis: clinical features, neuropathology and diagnostic criteria. Brain 1992 Apr; 115 (Pt 2): 495-520.
20. Menza MA, Cocchiola J, Golbe LI. Psychiatric symptoms in progressive supranuclear palsy. Psychosomatics 1995 Nov-Dec; 36 (6): 550-4.
21. Kim JS. Pathologic laughter after unilateral stroke. J Neurol Sci 1997 May 1; 148 (1): 121-5. (Pubitemid 27149534)
22. Nahas Z, Arlinghaus KA, Kotrla KJ, et al. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci 1998 Fall; 10 (4): 453-5. (Pubitemid 28505398)
23. Hargrave DR, Mabbott DJ, Bouffet E. Pathological laughter and behavioural change in childhood pontine glioma. J Neurooncol 2006 May; 77 (3): 267-71. (Pubitemid 44404392)
24. Parvizi J, Joseph J, Press DZ, et al. Pathological laughter and crying in patients with multiple system atrophycerebellar type. Mov Disord 2007 Apr 30; 22 (6): 798-803. (Pubitemid 46800100)
25. Seliger GM, Hornstein A, Flax J, et al. Fluoxetine improves emotional incontinence. Brain Inj 1992 May-Jun; 6 (3): 267-70.
26. Sloan RL, Brown KW, Pentland B. Fluoxetine as a treatment for emotional lability after brain injury. Brain Inj 1992 Jul-Aug; 6 (4): 315-9.
27. Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol 1996 Dec; 19 (6): 532-5. (Pubitemid 26391359)
28. Mü ller U, Murai T, Bauer-Wittmund T, et al. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj 1999 Oct; 13 (10): 805-11. (Pubitemid 29488207)
29. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985 Jun 6; 312 (23): 1480-2. (Pubitemid 15059233)
30. Robinson RG, Parikh RM, Lipsey JR, et al. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993 Feb; 150 (2): 286-93. (Pubitemid 23046517)
31. Andersen G, Vestergaard K, Riis JO. Citalopram for poststroke pathological crying. Lancet 1993 Oct 2; 342 (8875): 837-9.
32. Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatr Scand 1998 Dec; 98 (6): 455-8. (Pubitemid 28566296)
33. Burns A, Russell E, Stratton-Powell H, et al. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 1999 Aug; 14 (8): 681-5. (Pubitemid 29403287)
34. Murray V, von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 2005 Jun; 66 (6): 708-16. (Pubitemid 40942416)
35. Choi-Kwon S, Han SW, Kwon SU, et al. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke 2006 Jan; 37 (1): 156-61. (Pubitemid 43732065)
36. Moore SR, Gresham LS, Bromberg MB, et al. A self report measure of affective lability. J Neurol Neurosurg Psychiatry 1997 Jul; 63 (1): 89-93. (Pubitemid 27317366)
37. Panzer MJ, Mellow AM. Antidepressant treatment of pathologic laughing or crying in elderly stroke patients. J Geriatr Psychiatry Neurol 1992 Oct-Dec; 5 (4): 195-9.
38. Tsai WC, Lai JS, Wang TG. Treatment of emotionalism with fluoxetine during rehabilitation. Scand J Rehabil Med 1998 Sep; 30 (3): 145-9.
39. Mukand J, Kaplan M, Senno RG, et al. Pathological crying and laughing: treatment with sertraline. Arch Phys Med Rehabil 1996 Dec; 77 (12): 1309-11. (Pubitemid 26424847)
40. Okun MS, Riestra AR, Nadeau SE. Treatment of ballism and pseudobulbar affect with sertraline. Arch Neurol 2001 Oct; 58 (10): 1682-4. (Pubitemid 32963236)
41. Okun MS, Heilman KM, Vitek JL. Treatment of pseudobulbar laughter after gamma knife thalamotomy. Mov Disord 2002 May; 17 (3): 622-4. (Pubitemid 36040988)
42. Derex L, Ostrowsky K, Nighoghossian N, et al. Severe pathological crying after left anterior choroidal artery infarct: reversibility with paroxetine treatment. Stroke 1997 Jul; 28 (7): 1464-6. (Pubitemid 27300689)
43. Kosaka H, Omata N, Omori M, et al. Abnormal pontine activation in pathological laughing as shown by functional magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2006 Dec; 77 (12): 1376-80. (Pubitemid 44852001)
44. Andersen G, Stylsvig M, Sunde N. Citalopram treatment of traumatic brain damage in a 6-year-old boy. J Neurotrauma 1999 Apr; 16 (4): 341-4. (Pubitemid 29200827)
45. Kaschka WP, Meyer A, Schier KR, et al. Treatment of pathological crying with citalopram. Pharmacopsychiatry 2001 Nov; 34 (6): 254-8. (Pubitemid 33086860)
46. Allman P. Drug treatment of emotionalism following brain damage. J R Soc Med 1992 Jul; 85 (7): 423-4.
47. Parvizi J, Schiffer R. Exaggerated crying and tremor with a cerebellar cyst. J Neuropsychiatry Clin Neurosci 2007 Spring; 19 (2): 187-90. (Pubitemid 46649643)
48. Zellers GL, Frank M, Dougherty J. Pathological laughter. Ann Emerg Med 1990 Mar; 19 (3): 327-9. (Pubitemid 20064464)
49. Ramasubbu R. Lamotrigine treatment for post-stroke pathological laughing and crying. Clin Neuropharmacol 2003 Sep-Oct; 26 (5): 233-5. (Pubitemid 37221633)
50. KuboT,KobayashiO,NozakiM, et al.Successful thyrotropinreleasing hormone therapy for emotional incontinence and amnesia resulting from mumps encephalitis. Pediatr Infect Dis J 2004 Dec; 23 (12): 1175-6. (Pubitemid 40812773)
51. Kim SW, Shin IS, Kim JM, et al. Mirtazapine treatment for pathological laughing and crying after stroke. Clin Neuropharmacol 2005 Sep-Oct; 28 (5): 249-51.
52. Andersen G, Ingeman-Nielsen M, Vestergaard K, et al. Pathoanatomic correlation between poststroke pathological crying and damage to brain areas involved in serotonergic neurotransmission. Stroke 1994 May; 25 (5): 1050-2. (Pubitemid 24130315)
53. Parvizi J, Coburn KL, Shillcutt SD, et al. Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci 2009 Winter; 21: 75-87.
54. Parvizi J, Damasio AR. Neuroanatomical correlates of brainstem coma. Brain 2003 Jul; 126 (Pt 7): 1524-36. (Pubitemid 36834929)
55. McCall RB, Aghajanian GK. Serotonergic facilitation of facial motoneuron excitation. Brain Res 1979 Jun 15; 169 (1): 11-27. (Pubitemid 9176225)
56. Moller M, Andersen G, Gjedde A. Serotonin 5HT1A receptor availability and pathological crying after stroke. Acta Neurol Scand 2007 Aug; 116 (2): 83-90. (Pubitemid 47174187)
57. Brown JW. Physiology and phylogenesis of emotional expression. Brain Res 1967 May; 5 (1): 1-14.
58. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960 Feb; 23 (1): 56-62.
59. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961 Jun; 4: 561-71.
60. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979 Apr; 134: 382-9. (Pubitemid 9136500)
61. Choi DW, Peters S, Viseskul V. Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptormediated neurotoxicity on cortical neurons. J Pharmacol Exp Ther 1987 Aug; 242 (2): 713-20. (Pubitemid 17143508)
62. Klein M, Musacchio JM. High affinity dextromethorphan binding sites in guinea pig brain: effect of sigma ligands and other agents. J Pharmacol Exp Ther 1989 Oct; 251 (1): 207-15.
63. DeCoster MA, Klette KL, Knight ES, et al. Sigma receptormediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res 1995 Feb 6; 671 (1): 45-53.
64. Wroblewski JT, Danysz W. Modulation of glutamate receptors: molecular mechanisms and functional implications. Annu Rev Pharmacol Toxicol 1989; 29: 441-74. (Pubitemid 19107363)
65. Askmark H, Aquilonius SM, Gillberg PG, et al. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993 Feb; 56 (2): 197-200. (Pubitemid 23075416)
66. Blin O, Azulay JP, Desnuelle C, et al. A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis. Clin Neuropharmacol 1996 Apr; 19 (2): 189-92. (Pubitemid 26099377)
67. Vetticaden SJ, Cabana BE, Prasad VK, et al. Phenotypic differences in dextromethorphan metabolism. Pharm Res 1989 Jan; 6 (1): 13-9.
68. Zhang Y, Britto MR, Valderhaug KL, et al. Dextromethorphan: enhancing its systemic availability by way of lowdose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992 Jun; 51 (6): 647-55.
69. Smith RA, Moore S, Gresham L, et al. The treatment of affective lability with dextromethorphan. American Academy of Neurology 47th Annual Meeting [abstract no. 604P]. Neurology 1995; 45 Suppl. 4: A330.
70. Holford NH, Coates PE, Guentert TW, et al. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration-effect relationships. Br J Clin Pharmacol 1981 Feb; 11 (2): 187-95. (Pubitemid 11167986)
71. Smith RA, Berg JE, Pope LE, et al. Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler 2004 Dec; 10 (6): 679-85. (Pubitemid 39585248)
72. Brooks BR, Cummings J, Pioro EP, et al. Pharmacokinetic/pharmacodynamic modeling of dextromethorphan/quinidine for a study in pseudobulbar affect [abstract T 172]. Presented at the American Neurological Association's 133rd Annual Meeting; 2008 Sep 21-24; Salt Lake City (UT).
73. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio (TX): Psychological Corporation, 1996.
74. Pioro EP, Brooks BR, Cummings J, et al. Persistent efficacy of dextromethorphan/quinidine for pseudobulbar affect: results from a 12-week, open-label extension study [poster P02.295]. Presented at the 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10-17; Toronto (ON).
75. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 Jun; 30 (6): 473-83.
76. Swinkels JA, de Jonghe F. Safety of antidepressants. Int Clin Psychopharmacol 1995 Jan; 9 Suppl. 4: 19-25.
77. Pollock BG, Mulsant BH, Nebes R, et al. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry 1998 Aug; 155 (8): 1110-2. (Pubitemid 28357741)
78. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000 Apr; 58 (1): 19-36. (Pubitemid 30173208)
79. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000 Apr; 56 (1): 1-18. (Pubitemid 30317776)
80. Haiman G, Pratt H, Miller A. Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect. J Neurol Sci 2008 Aug 15; 271 (1-2): 137-47.
81. Haiman G, Pratt H, Miller A. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect. J Clin Psychopharmacol 2009 Oct; 29 (5): 444-52